SOMERSET, N.J.—August 15, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its unaudited financial results for the three and six months ended June 30, 2023. In addition to financial performance, Legend Biotech reported on the success of its portfolio […]

SOMERSET, N.J.—August 3, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, will host a conference call for investors at 8:00am Eastern Time on Tuesday, August 15, 2023 to review second-quarter results. Company executives will provide an overview of Legend Biotech’s performance […]

The application is supported by the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival compared to standard regimens CARTITUDE-4 is the first randomized Phase 3 study investigating the efficacy and safety of cell therapy as early as after first relapse in multiple myeloma SOMERSET, N.J.—June 6, 2023—Legend Biotech Corporation […]

SOMERSET, N.J.—June 5, 2023 — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that results from the Phase 3 CARTITUDE-4 study showed that, at a median follow up of 16 months, cilta-cel reduced the risk of disease progression or death […]

The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy Somerset, N.J. – May 25, 2023 – Legend Biotech Corporation (NASDAQ: […]